基本情報
- CAS
128326-82-9- 標準SMILES
Clc1cc(Cl)c2c(c1)CCc1ccccc1C2n1ccnc1- InChIKey
MPTJIDOGFUQSQH-UHFFFAOYSA-N- 分子式
- C18H14Cl2N2
- 平均分子量
- 329.2 g/mol
- 単同位体質量
- 328.0534038
概要
1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole is a member of the class of dibenzannulenes that is 10,11-dihydrodibenzo[a,d][7]annulene carrying two chloro substituents at positions 2 and 4 as well as an imidazol-1-yl substituent at position 5. It is a member of imidazoles, a dibenzannulene and an organochlorine compound. It derives from a hydride of a dibenzo[a,d][7]annulene.
名称と識別子
- 優先名称
- Eberconazole
- IUPAC
- 1-(4,6-dichloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)imidazole
- 現地名
- エベルコナゾール
- 英語名
- Eberconazole
- 分子式
- C18H14Cl2N2
- 分子量
- 329.22
名称と別名
Eberconazole128326-82-9EberconazolEberconazolumV7O1U41C9BDTXSID909261041-(2,4-dichloro-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-1H-imidazoleRefChem:920795CHEBI:82862D01AC17DTXCID6013549231-(4,6-dichlorotricyclo(9.4.0.0^(3,8))pentadeca-1(15),3,5,7,11,13-hexaen-2-yl)-1H-imidazole
名称をさらに表示
エベルコナゾールrac-1-[(2,4-ジクロロ-10,11-ジヒドロ-5H-ジベンゾ[a,d]シクロヘプテン)-5α*-イル]-1H-イミダゾールrac-1-[[(5R*)-2,4-ジクロロ-10,11-ジヒドロ-5H-ジベンゾ[a,d]シクロヘプテン]-5-イル]-1H-イミダゾール1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(+/-)-1-(2,4-Dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)imidazole
Eberconazole [INN]1-(4,6-dichloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)imidazole1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-1H-imidazoleEberconazole (INN)Eberconazol [INN-Spanish]Eberconazolum [INN-Latin]UNII-V7O1U41C9BWAS-2160
データベース識別子
物性
構造計算による物性
- XLogP
- 4.9
- 極性表面積
- 17.8 Ų
- 水素結合供与体数
- 0
- 水素結合受容体数
- 1
- 回転可能結合数
- 1
- 重原子数
- 22
- 形式電荷
- 0
- 複雑度
- 391
物理化学的性質
- 沸点
- 495 · 495.0±45.0 °C(Predicted)
- 比重(密度)
- 1.35 · 1.35±0.1 g/cm3(Predicted)
- 酸解離定数(Pka)
- 5.84 · 5.84±0.10(Predicted)
化学と産業
薬理情報
ATC Code
D - Dermatologicals
QD - Dermatologicals
PharmacodynamicsEberconazole is active against Gram-positive bacteria, dermatophytes, and yeasts.
Mechanism of ActionEberconazole shares a mechanism of action with other antimycotic azoles: It inhibits lanosterol 14a-demethylase, thereby blocking the synthesis of precursors of ergosterols.
応用分野
説明Eberconazole is a new member of the azole class of antifungal agents, and it is indicated for the topical treatment of cutaneous fungal infections, including tinea corporis (ringworm of the body), tinea cruris (ringworm of the groin) and tinea pedis (athlete’s foot) infections. Its mode of action is similar to that of other azole antifungals, namely inhibition of fungal lanosterol 14α-demethylase. Eberconazole exhibits good in vitro activity against a wide range of Candida species, including Candida. tropicalis, dermatophytes and Malassezia spp. yeasts. It shows good activity against Candida. Parapsilosis (MIC90=0.125 mg/mL), which is a relevant species in skin and nail disorders. In addition, eberconazole is effective against some of the highly triazole-resistant yeasts such as Candida. glabrata and Candida. krusei, as well as fluconazole-resistant Candida. albicans. However, eberconazole is less active than clotrimazole and ketoconazole against Candida. neoformans and a number of clinically relevant molds. Eberconazole is supplied as a 1% or 2% cream, and the topical application does not result in detectable serum, urine, or fecal levels. In a phase II study of 60 patients with tinea corporis and tinea cruris, treatment with topical eberconazole (1% or 2% cream), applied once or twice daily for 6 weeks, resulted in cure rates ranging from 73.3–93.3% at the end of therapy, and 66.7–100% six weeks post-therapy.
使用Eberconazole can be used for a novel antifungal formulation.
サプライヤー9 社
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…